Related Experiment Video

Updated: Feb 13, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

2.3K

Progress in the Management of Malignant Pleural Mesothelioma in 2017

Amanda J McCambridge1, Andrea Napolitano2, Aaron S Mansfield3

  • 1Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|March 11, 2018
PubMed

Insights

Advances in malignant pleural mesothelioma (MPM) treatment in 2017 focused on understanding its molecular pathogenesis and tumor microenvironment. New immunotherapies and targeted drugs like ADI-PEG20 and tazemetostat show promise for this asbestos-induced cancer.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer linked to asbestos exposure.
  • Effective diagnostic, prognostic, and therapeutic strategies for MPM remain critical due to its poor survival rates.
  • Recent epidemiological data indicate a continued rise in MPM-related deaths in the United States.

Purpose of the Study:

  • To review significant advancements in malignant pleural mesothelioma research and treatment strategies reported in 2017.
  • To highlight emerging insights into the molecular underpinnings and immune landscape of MPM.
  • To identify promising novel therapeutic targets and clinical trial directions for MPM.

Main Methods:

  • Review of epidemiological data on MPM incidence and mortality.
  • Analysis of research into the molecular pathogenesis, including BRCA1 associated protein 1 (BAP1) and programmed death-receptor ligand 1 (PD-L1) expression.
  • Survey of ongoing clinical trials investigating systemic therapies for MPM, including immunotherapies and targeted agents.

Main Results:

  • Increased understanding of MPM's molecular pathogenesis and immunological tumor microenvironment.
  • Identification of BAP1 and PD-L1 as key factors in MPM development and potential therapeutic targets.
  • Active clinical investigation of immune checkpoint inhibitors, other immunotherapies, and targeted agents like ADI-PEG20 and tazemetostat.

Conclusions:

  • Emerging research in 2017 provided new insights into MPM's molecular and immunological characteristics.
  • Novel therapeutic strategies, including immunotherapy and targeted agents, are under active clinical investigation for MPM.
  • Continued research is essential to develop more effective treatments for this challenging asbestos-induced malignancy.
Keywords:
BAP1ImmunotherapyMesothelinMesotheliomaReviewTherapy

More Related Videos

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

7.3K
Local Anesthetic Thoracoscopy for Undiagnosed Pleural Effusion03:22

Local Anesthetic Thoracoscopy for Undiagnosed Pleural Effusion

Published on: November 10, 2023

1.6K

Related Concept Videos

Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
820
Pleural Effusion I: Introduction01:25

Pleural Effusion I: Introduction

Pleural effusion is an abnormal fluid accumulation in the pleural cavity, a narrow space between the lungs and the chest wall. It is not a disease per se but rather a symptom or indication of an underlying disease. In normal circumstances, this space contains a small amount of fluid (5 to 15 mL), a lubricant facilitating the non-frictional movement of the pleural surfaces.
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
4.5K
Pleural Disorders: Types and Brief Description01:30

Pleural Disorders: Types and Brief Description

The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
721
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Tonsillitis II: Management01:26

Tonsillitis II: Management

This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
446